Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial

Autor: M. Chassain-Le Lay, M. Schollhammer, A.-M. Roguedas-Contios, Emilie Brenaut, Laurent Misery, N. Ménard-Andivot, M. Greco, G. Le Gal, C. Gouedard, C. Abasq-Thomas, A. Zagnoli, Y. Le Ru, M. Pillette-Delarue, K. Penven, Bruno Sassolas, D. Dupré-Goetghebeur, N. Jouan
Přispěvatelé: Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, LabEX IGO Immunothérapie Grand Ouest, Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Ottawa Hospital Research Institute [Ottawa] (OHRI)
Rok vydání: 2015
Předmět:
Adult
Male
Adolescent
[SDV]Life Sciences [q-bio]
Placebo-controlled study
Muscarinic Antagonists
Dermatology
Placebo
Xerostomia
Generalized hyperhidrosis
law.invention
Young Adult
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Randomized controlled trial
law
medicine
Humans
Hyperhidrosis
Prospective Studies
030212 general & internal medicine
Oxybutynin
Prospective cohort study
Dose-Response Relationship
Drug
business.industry
Dermatology Life Quality Index
Middle Aged
medicine.disease
3. Good health
Treatment Outcome
Patient Satisfaction
Anesthesia
Quality of Life
Mandelic Acids
Female
medicine.symptom
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
medicine.drug
Zdroj: British Journal of Dermatology
British Journal of Dermatology, Wiley, 2015, 173 (5), pp.1163-8. ⟨10.1111/bjd.13973⟩
ISSN: 0007-0963
1365-2133
DOI: 10.1111/bjd.13973
Popis: SummaryBackground Hyperhidrosis is a disorder that can impair quality of life. Localized treatments may be cumbersome and ineffective, and no systemic treatments have proven to be significantly beneficial. Objectives To evaluate the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis. Methods We conducted a prospective, randomized, placebo-controlled trial. From June 2013 to January 2014, 62 patients with localized or generalized hyperhidrosis were enrolled. Oxybutynin was started at a dose of 2·5 mg per day and increased gradually to 7·5 mg per day. The primary outcome was defined as improvement of at least one point on the Hyperhidrosis Disease Severity Scale (HDSS). Dermatology Life Quality Index (DLQI) and tolerance were also reported. Results Most patients (83%) in our study had generalized hyperhidrosis. Oxybutynin was superior to placebo in improving the HDSS: 60% of patients treated with oxybutynin, compared with 27% of patients treated with placebo, improved at least one point on the HDSS (P = 0·009). The mean improvement in quality of life measured by DLQI was significantly better in the oxybutynin arm (6·9) than in the placebo arm (2·3). The most frequent side-effect was dry mouth, which was observed in 43% of the patients in the oxybutynin arm, compared with 11% in the placebo arm. Conclusions Treatment with low-dose oxybutynin is effective in reducing symptoms of hyperhidrosis in generalized or localized forms. Side-effects were frequent but minor and mainly involved dry mouth.
Databáze: OpenAIRE
Externí odkaz: